Meningococcal Vaccines Market Growth in the United States has Risen Dramatically – Industry Forecast, 2020-2026
Pune, Maharashtra, India, September 15 2020 (Wiredrelease) Allied Analytics –:Global Meningococcal vaccines market size was valued at $1,935.54 million in 2018, and is projected to reach $4.19 billion by 2026, registering a CAGR of 9.5% from 2019 to 2026.
Bacterial infections can be prevented by immunization and therefore, immunization is crucial. Neisseria meningitidis, is a virus that causes diseases such as meningitis, bacteremia (meningococcemia), and bacteremia pneumonia. However, these infectious diseases can be prevented by the use of meningococcal vaccines. Meningococcal vaccines are administered to both children and adults in a pattern of two doses to ensure complete immunization. There are three different types of meningococcal vaccines such as conjugate, polysaccharide, and subcapsular meningococcal vaccines.
Download Free Sample Report @ https://www.alliedmarketresearch.com/request-sample/330
Due to lockdown, immunization programs will come to a halt and program schedules will be changed in various countries.Research and development activities for vaccine technology will be limited, as researchers need to stay at home during the lockdown.Meningococcal vaccine is used as a placebo effect in the Covid-19 vaccine trial conducted at the University of Oxford.
The MenACWY vaccine segment to maintain its highest share during the forecast period
Based on vaccine serotype, the MenACWY vaccine segment contributed to the highest market share in 2018, accounting for nearly half of the global meningococcal vaccine market, and is estimated to maintain its highest share during the forecast period. This is attributed to rise in awareness regarding the usage of meningococcal vaccine to treat meningitis disease. However, the MenA vaccine segment is estimated to witness the fastest CAGR of 13.5% from 2019 to 2026, owing to surge in the routine immunization programs worldwide.
The conjugate segment to maintain its lead by 2026
Based on vaccine type, the conjugate segment held the largest share of the global meningococcal vaccine market, accounting for nearly half of the total market share in 2018, and is estimated to maintain its lead by 2026. Moreover, this segment is estimated to grow at the highest CAGR of 10.2% from 2019 to 2026. This is attributed to usage of vaccines in routine immunization schedules, preventive campaigns, and outbreak responses. The research also analyzes segments including polysachharide and subcapsular.
For Purchase Enquiry at: https://www.alliedmarketresearch.com/purchase-enquiry/330
North America to maintain its dominance throughout the forecast period
Based on region, North America accounted for the largest market share in terms of revenue in 2018, holding nearly half of the global meningococcal vaccine market, and is estimated to maintain its lead position throughout the forecast period. This is due to surge in prevalence of meningitis disease and ease in availability of meningococcal vaccine products for treatment of the disease. However, Asia-Pacific is expected to portray the largest CAGR of 14.7% from 2019 to 2026, owing to surge in outbreaks of meningococcal diseases and widespread availability of products.
Leading market players
Bio-ManguinhosBio-Med Pvt. LimitedChongqing Zhifei Biological Products Co., Ltd.GlaxoSmithKline PlcHualan Biological Engineering Inc.Incepta Pharmaceuticals Ltd.Pfizer Inc.Sanofi S.A.Serum Institute of India Pvt. Ltd.Walvax Biotechnology Co., Ltd.
This content has been published by Allied Analytics company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at firstname.lastname@example.org.